Function of ranibizumab intraocular injection in the control of neovascular glaucoma

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-13003646

Enrollment

Unknown

Registered

2013-09-28

Start date

2013-10-29

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neovascular glaucoma

Interventions

Case series:intraocular injection

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. neovascualr glaucoma secondary to diabetic retinopathy, retinal vein occulusion, et al.; 2. not sensitive to local anti-glaucoma medicine; 3. not blind.

Exclusion criteria

Exclusion criteria: 1. previous operation; 2. eye atrophy.

Design outcomes

Primary

Measure	Time frame
intraocular pressure;	—

Countries

China

Contacts

Public ContactXuejiao Qin

Qilu Hospital of Shandong University

qinxuejiao@hotmail.com+86 13505311019

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026